The Centers for Disease Control and Prevention (CDC) Updates Handwashing Guidelines and Materials
18.3.2021 17:52:00 EET | Business Wire | Press release
The Centers for Disease Control and Prevention (CDC) recently updated handwashing guidelines, standardizing language and updating visuals. Though hand dryers have always been recommended by the organization, language around the topic of hand drying was inconsistent across industries and materials. Now, with the latest updates, the CDC’s stance is unequivocally clear: hand dryers are a supported hand drying solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005663/en/
The CDC supports hand dryers for hand hygiene. (Graphic: Business Wire)
The CDC has shared that “germs spread more easily when hands are wet” and recommends thorough hand drying with clean towels or hand dryers to mitigate germ transfer and the spread of viruses like COVID-19. The organization’s robust hand hygiene media library now visually depicts both towels and hand dryers as a means to complete hygienic hand drying in materials supporting the Stop Germs! Wash Your Hands campaign including fact sheets, posters and other downloadable assets. Additionally, CDC hand drying FAQs and reopening guidelines across industries, including schools, make specific mention of hand dryers among recommended supplies to have on hand.
“Hand drying is a critical step of proper hand hygiene but has not received the same media attention that handwashing has throughout the pandemic,” shared William Gagnon, vice president of marketing and sales at Excel Dryer. “Ask most anyone how long you should wash your hands and they’re likely to respond with ’20 seconds’ or ‘the amount of time it takes to sing Happy Birthday twice.’ I don’t believe they realize how important hand drying is to the process and am hopeful the updated materials will help to mitigate confusion and, in turn, the virus’ spread.”
Excel Dryer’s line of sensor-activated, touchless hand dryers have long been trusted to achieve proper hand hygiene by retail stores, airports, restaurants, schools and universities, stadiums and arenas, hospitals and healthcare facilities, public safety complexes—and any commercial facility with public and/or employee restrooms.
The CDC’s updated guidelines provide peace of mind to facility managers and members of the public who will interact with hand dryers as these sites reopen.
“We encourage policy makers, owners, operators and any decision makers or organizations responsible for commercial facilities to consult the updated CDC hygiene resources when reopening guidelines are formulated,” furthered Gagnon. “In some instances, these guidelines will need to be updated to correct incorrect guidance on the use of hand dryers. The CDC has made this point clear: hand dryers are recommended.”
To review the CDC’s handwashing recommendations, visit cdc.gov/handwashing/when-how-handwashing.html. To learn more about Excel Dryer’s hygienic hand drying solutions, visit: exceldryer.com.
About Excel Dryer, Inc.
Excel Dryer has been manufacturing the finest American-made hand dryers for more than 50 years. The family-owned and -operated company revolutionized the industry with the invention of the patented XLERATOR® Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer prides itself on offering the best customer service and making hygienic, cost-effective and sustainable products people can depend on. Available for distribution worldwide, Excel Dryer products can be purchased through an established network of sales representatives who call on more than 5,000 distributors globally. Learn more about Excel Dryer at
exceldryer.com
.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005663/en/
Contact information
Lisa Twarog or Michelle Abdow
(Office) 413-787-1133
ltwarog@marketmentors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom